Lv4
610 积分 2023-07-08 加入
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases
11天前
已完结
Structure-Based Discovery of a New LpxH-Targeted Chemotype with Activity against Klebsiella pneumoniae
13天前
已完结
Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability
13天前
已完结
Structure-Based Design of Potent and Highly Selective NUAK1 Inhibitors by Exploiting a Unique Glutamate Switch for the Prevention of Tumor Growth, Migration, and Invasion
13天前
已完结
Potent Benzothiazole-Triazole RIPK1/RIPK3 Dual-Targeting Inhibitors for the Treatment of Systemic Inflammatory Response Syndrome
13天前
已完结
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole
21天前
已完结
Design, Synthesis, and Anti-inflammatory Activity Evaluation for Hydrazide-Based HDAC6 Targeted Protein Degraders
25天前
已完结
Mechanistic Characterization of a Small Molecule as a Direct NLRP3 Inhibitor via Binding to the NACHT Domain
25天前
已完结
JAK Inhibition: The Most Promising Agents in the IBD Pipeline?
1个月前
已完结
Mechanisms of Disease: Inflammatory Bowel Diseases
1个月前
已完结
皖公网安备34019202002308
